[go: up one dir, main page]

PE20211412A1 - Anticuerpos anti-gdf15, composiciones y metodos de uso - Google Patents

Anticuerpos anti-gdf15, composiciones y metodos de uso

Info

Publication number
PE20211412A1
PE20211412A1 PE2021000234A PE2021000234A PE20211412A1 PE 20211412 A1 PE20211412 A1 PE 20211412A1 PE 2021000234 A PE2021000234 A PE 2021000234A PE 2021000234 A PE2021000234 A PE 2021000234A PE 20211412 A1 PE20211412 A1 PE 20211412A1
Authority
PE
Peru
Prior art keywords
compositions
methods
gdf15
antibodies
gdf15 antibodies
Prior art date
Application number
PE2021000234A
Other languages
English (en)
Inventor
James R Apgar
Kevin Charles Beaumont
Danna M Breen
Jeffrey Raymond Chabot
Tao He
Matthew Allister Lambert
Ksenya Shchors
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69232873&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20211412(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of PE20211412A1 publication Critical patent/PE20211412A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invencion se relaciona con anticuerpos y fragmentos de union al antigeno de los mismos, que unen especificamente el factor 15 de diferenciacion del crecimiento (GDF15) y con composiciones, metodos y usos de los mismos, que incluyen los usos de la combinacion de un anticuerpo anti-GDF15 de la invencion y un antagonista de union al eje PD-1 y/o un inhibidor CD40 para tratar cancer.
PE2021000234A 2018-08-20 2019-08-15 Anticuerpos anti-gdf15, composiciones y metodos de uso PE20211412A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862765289P 2018-08-20 2018-08-20
US201862750479P 2018-10-25 2018-10-25
US201862750393P 2018-10-25 2018-10-25
US201962881064P 2019-07-31 2019-07-31
PCT/IB2019/056932 WO2020039321A2 (en) 2018-08-20 2019-08-15 Anti-gdf15 antibodies, compositions and methods of use

Publications (1)

Publication Number Publication Date
PE20211412A1 true PE20211412A1 (es) 2021-08-02

Family

ID=69232873

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021000234A PE20211412A1 (es) 2018-08-20 2019-08-15 Anticuerpos anti-gdf15, composiciones y metodos de uso

Country Status (17)

Country Link
US (3) US11566066B2 (es)
EP (1) EP3841121A2 (es)
JP (2) JP7155403B2 (es)
KR (1) KR102715542B1 (es)
CN (1) CN112912395B (es)
AU (1) AU2019323790A1 (es)
BR (1) BR112021003173A2 (es)
CA (1) CA3109905A1 (es)
CO (1) CO2021001893A2 (es)
IL (1) IL280963A (es)
MX (1) MX2021001841A (es)
MY (1) MY205789A (es)
PE (1) PE20211412A1 (es)
PH (1) PH12021550337A1 (es)
SG (1) SG11202101502YA (es)
TW (1) TWI803682B (es)
WO (1) WO2020039321A2 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015532271A (ja) 2012-09-26 2015-11-09 ユリウス・マクシミリアンス−ウニヴェルジテート・ヴュルツブルクＪｕｌｉｕｓ Ｍａｘｉｍｉｌｉａｎｓ−Ｕｎｉｖｅｒｓｉｔａｅｔ Ｗｕｅｒｚｂｕｒｇ 増殖分化因子１５（ｇｄｆ−１５）に対するモノクローナル抗体
FI3356827T3 (fi) 2015-10-02 2024-01-03 Univ Wuerzburg J Maximilians GDF-15 diagnostisena markkerina immuunivasteen vapauttajilla annetun hoidon hoitovasteen ennustamiseksi
BR112018006218A2 (pt) 2015-10-02 2018-10-09 Univ Wuerzburg J Maximilians iinibidores de hgdf-15, seus usos, composição, kit, combinações e método in vitro para determinar se uma substância de interesse é um inibidor de hgdf-15
SG11201807279QA (en) 2016-03-31 2018-09-27 Ngm Biopharmaceuticals Inc Binding proteins and methods of use thereof
EP3558363A1 (en) 2016-12-21 2019-10-30 Amgen Inc. Anti-tnf alpha antibody formulations
SG11202101502YA (en) * 2018-08-20 2021-03-30 Pfizer Anti-gdf15 antibodies, compositions and methods of use
WO2021167883A1 (en) * 2020-02-21 2021-08-26 The Children's Medical Center Corporation Method for treating asthma or allergic disease
CN115968285A (zh) * 2020-03-18 2023-04-14 Gmp生物技术有限公司 TGF-β抑制、用于其的药剂及组合物
IL298159A (en) * 2020-05-13 2023-01-01 Pfizer Treatment methods and uses for cancer treatment
US20230338396A1 (en) * 2020-05-14 2023-10-26 Augusta University Research Institute, Inc. Cannabidiol as a therapeutic modality for covid-19
KR20230095097A (ko) * 2020-10-30 2023-06-28 히데아키 하라 눈 조직 섬유화의 저해에 사용하기 위한 gdf15 조절 물질
IL302646A (en) * 2020-11-10 2023-07-01 Catalym Gmbh Anti-GDF15 antibody and dosage regimen for cancer treatment
AU2022269145A1 (en) * 2021-05-07 2023-12-21 Innovent Biologics (Suzhou) Co., Ltd. Fc mutant with altered binding to fc receptor
WO2022255401A1 (ja) * 2021-06-03 2022-12-08 国立大学法人 東京大学 Ｅｒｋ－ｍａｐｋ経路の異常な活性化に伴い発現する疾患マーカー
US20250019427A1 (en) * 2021-08-10 2025-01-16 Byomass Inc. Anti-gdf15 antibodies, compositions and uses thereof
TW202313694A (zh) * 2021-09-10 2023-04-01 美商恩格姆生物製藥公司 治療癌症以及腫瘤相關之體重減輕及惡病質之方法
WO2023048425A1 (ko) * 2021-09-24 2023-03-30 재단법인대구경북과학기술원 친화도가 개선된 gfral 길항 항체 및 이의 용도
KR102864956B1 (ko) * 2021-09-24 2025-09-30 재단법인대구경북과학기술원 친화도가 개선된 gfral 길항 항체 및 이의 용도
WO2023079430A1 (en) * 2021-11-02 2023-05-11 Pfizer Inc. Methods of treating mitochondrial myopathies using anti-gdf15 antibodies
WO2023122213A1 (en) 2021-12-22 2023-06-29 Byomass Inc. Targeting gdf15-gfral pathway cross-reference to related applications
US20250092124A1 (en) * 2022-01-26 2025-03-20 Yunnan Baiyao Group Co., Ltd. Antibody molecule against growth and differentiation factor 15 and use thereof
WO2023217068A1 (zh) * 2022-05-09 2023-11-16 舒泰神（北京）生物制药股份有限公司 特异性识别gdf15的抗体及其应用
AU2023336580A1 (en) 2022-09-08 2025-03-13 Catalym Gmbh Anti-gdf15 antibody used in a combination treatment of specific patient groups and a dosage regimen for the treatment of cancer
KR20240116658A (ko) * 2023-01-20 2024-07-30 한국과학기술원 Gfral을 표적으로 하는 안티센스 올리고머 및 이의 용도
IL322807A (en) * 2023-02-17 2025-10-01 Endevica Bio Inc Methods for preventing and/or treating side effects associated with the use of anticancer agents, using unnatural melanocortin analogs in combination with antibodies against GDF-15
CN116444667B (zh) * 2023-06-13 2023-09-01 上海驯鹿生物技术有限公司 一种靶向gdf15的全人源抗体及其应用
WO2025113639A1 (zh) * 2023-11-30 2025-06-05 南京维立志博生物科技股份有限公司 抗gdf15的抗体及其方法和用途
WO2025146488A1 (en) 2024-01-05 2025-07-10 Catalym Gmbh Anti-hgdf-15 antibody for use in the treatment of cancer in a patient in combination with a cancer antigen-targeted drug conjugate that induces cancer cell stress
WO2025245200A1 (en) 2024-05-24 2025-11-27 Pfizer Inc. Ponsegromab for use in treating cachexia in cancer patients

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
JP2005512044A (ja) 2001-12-03 2005-04-28 アブジェニックス・インコーポレーテッド 結合特性に基づく抗体分類
CA2511598C (en) 2002-12-24 2016-09-13 Rinat Neuroscience Corp. Anti-ngf antibodies and methods using same
PL2441466T3 (pl) 2004-04-13 2015-01-30 St Vincents Hospital Sydney Ltd Środek hamujący MIC-1
CA2694863A1 (en) 2007-08-16 2009-02-19 Garvan Institute Of Medical Research Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity
MX2011002250A (es) 2008-08-25 2011-08-17 Amplimmune Inc Antagonistas de muerte celular programada-1 y métodos de uso de los mismos.
JP2013512251A (ja) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
KR101962483B1 (ko) * 2010-11-17 2019-03-29 추가이 세이야쿠 가부시키가이샤 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
LT2785375T (lt) 2011-11-28 2020-11-10 Merck Patent Gmbh Anti-pd-l1 antikūnai ir jų panaudojimas
EP3689370A1 (en) * 2012-12-21 2020-08-05 Aveo Pharmaceuticals Inc. Anti-gdf15 antibodies
LT3653644T (lt) * 2014-03-26 2024-01-25 Julius-Maximilians-Universität Würzburg Monokloniniai antikūnai prieš augimo ir diferenciacijos faktorių 15 (gdf- 15), ir jų panaudojimas taikant vėžio kacheksijos ir vėžio gydymą
WO2015196142A1 (en) 2014-06-20 2015-12-23 Aveo Pharmaceuticals, Inc. Treatment of congestive heart failure and other cardiac dysfunction using a gdf15 modulator
KR102443258B1 (ko) * 2014-08-12 2022-09-14 엘리게이터 바이오사이언스 에이비 항 cd40 항체에 의한 병용 치료제
EP3197493B1 (en) 2014-09-25 2021-03-10 Aveo Pharmaceuticals Inc. Methods of reversing cachexia and prolonging survival comprising administering a gdf15 modulator and an anti-cancer agent
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
US10647756B2 (en) 2015-05-18 2020-05-12 Pfizer Inc. Humanized antibodies
SG11202101502YA (en) 2018-08-20 2021-03-30 Pfizer Anti-gdf15 antibodies, compositions and methods of use

Also Published As

Publication number Publication date
WO2020039321A3 (en) 2020-05-07
JP7155403B2 (ja) 2022-10-18
WO2020039321A8 (en) 2020-10-01
AU2019323790A1 (en) 2021-03-11
US20220380448A1 (en) 2022-12-01
TW202021619A (zh) 2020-06-16
US20200055930A1 (en) 2020-02-20
JP2021526847A (ja) 2021-10-11
EP3841121A2 (en) 2021-06-30
PH12021550337A1 (en) 2021-10-04
KR20210049840A (ko) 2021-05-06
WO2020039321A2 (en) 2020-02-27
US11566066B2 (en) 2023-01-31
MY205789A (en) 2024-11-13
CA3109905A1 (en) 2020-02-27
CO2021001893A2 (es) 2021-03-08
US20250326829A1 (en) 2025-10-23
US12227564B2 (en) 2025-02-18
CN112912395A (zh) 2021-06-04
NZ773036A (en) 2025-03-28
MX2021001841A (es) 2021-05-13
KR102715542B1 (ko) 2024-10-08
BR112021003173A2 (pt) 2021-05-11
TWI803682B (zh) 2023-06-01
SG11202101502YA (en) 2021-03-30
JP2022188191A (ja) 2022-12-20
IL280963A (en) 2021-04-29
CN112912395B (zh) 2024-08-23

Similar Documents

Publication Publication Date Title
PE20211412A1 (es) Anticuerpos anti-gdf15, composiciones y metodos de uso
CL2024002250A1 (es) Uso de anticuerpo anti-vd1 para tratar cáncer, una enfermedad infecciosa o una enfermedad inflamatoria.
BR112021019334A2 (pt) Anticorpos de cadeia pesada que se ligam ao psma
CO2021008696A2 (es) Moléculas agonistas de unión al antígeno cd28 que actúan sobre el tumor
MX2021012769A (es) Anticuerpos bloqueadores cd73.
CO2020000214A2 (es) Anticuerpos agonistas que se unen a cd137 humano y sus usos
BR112022004451A2 (pt) Antagonistas de hpk1 e usos dos mesmos
MX2021002690A (es) Anticuerpos anti-avb8 y composiciones y usos de los mismos.
CL2019001740A1 (es) Novedoso conjugado de amanitina.
CR20170600A (es) Anticuerpos del factor x1 y métodos de uso
PE20181367A1 (es) Anticuerpos agonistas que se unen especificamente a cd40 humana y metodos de uso
BR112018071307A2 (pt) anticorpos agonistas que ligam cd40 humana e usos dos mesmos
AR111288A1 (es) Anticuerpos anti-phf-tau y sus usos
CR20190330A (es) Anticuerpos anti-ox40 y sus usos
CL2008003361A1 (es) Anticuerpos monoclonales que se unen al hgm-csf y las composicones medias que los comprenden.
MX2017000985A (es) Anticuerpos anti-pd-1.
BR112019001206A2 (pt) anticorpos monoclonais humanizados que visam ve-ptp (hptp-ss)
MX2023004869A (es) Anticuerpos contra sars-cov-2 y usos de los mismos.
MX2022007959A (es) Nuevos anticuerpos anti-fgfr2b.
CL2017002705A1 (es) Anticuerpos que se dirigen a la proteína morfogénica ósea 9 (bmp9) y a los métodos a los que se refieren
CL2023003695A1 (es) Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, métodos de uso
CL2021001615A1 (es) Anticuerpos anti il-36 y procedimientos de uso de estos
CL2021001607A1 (es) Anticuerpos anti-pmel17 y conjugados de los mismos
CL2025000292A1 (es) Anticuerpos tmem219 y usos terapéuticos de los mismos
CO2023000557A2 (es) Anticuerpos y métodos para tratar enfermedades asociadas a claudina